Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from AbSci ( (ABSI) ).
On November 12, 2025, Absci Corporation reported its third-quarter financial and operating results, highlighting significant advancements in its pipeline. The company is focusing on ABS-201, targeting androgenetic alopecia and endometriosis, with clinical trials scheduled for late 2025 and 2026. Absci’s strategic shift involves reallocating resources to ABS-201 due to its high unmet medical need and market potential, while exploring partnerships for ABS-101. The company reported a net loss of $28.7 million for the quarter but has sufficient cash reserves to fund operations until the first half of 2028.
The most recent analyst rating on (ABSI) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on AbSci stock, see the ABSI Stock Forecast page.
Spark’s Take on ABSI Stock
According to Spark, TipRanks’ AI Analyst, ABSI is a Neutral.
AbSci’s overall stock score is primarily impacted by its weak financial performance, characterized by negative profitability and cash flow metrics. While the earnings call provided some positive developments in clinical trials and strategic partnerships, these are offset by increased R&D expenses and low revenue. Technical analysis shows mixed signals, and the valuation remains unattractive due to ongoing losses.
To see Spark’s full report on ABSI stock, click here.
More about AbSci
Absci Corporation is a clinical-stage biopharmaceutical company that leverages generative AI to advance breakthrough therapeutics. The company focuses on creating innovative biologics and has an Integrated Drug Creation™ platform that combines AI models with synthetic biology to design therapeutics addressing challenging targets. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City and an Innovation Center in Switzerland.
Average Trading Volume: 5,211,255
Technical Sentiment Signal: Hold
Current Market Cap: $496.4M
See more insights into ABSI stock on TipRanks’ Stock Analysis page.